In this prespecified secondary analysis from the High-STEACS trial, we have evaluated the use of risk stratification thresholds for high-sensitivity cardiac troponin I in 32 837 consecutive patients with suspected acute coronary syndrome. This evidence concerns the gene TNNI3 and acute coronary syndrome.